172 related articles for article (PubMed ID: 32130533)
1. Exploring the ring potential of 2,4-diaminopyrimidine derivatives towards the identification of novel caspase-1 inhibitors in Alzheimer's disease therapy.
Kumi RO; Soremekun OS; Issahaku AR; Agoni C; Olotu FA; Soliman MES
J Mol Model; 2020 Mar; 26(4):68. PubMed ID: 32130533
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design, synthesis and evaluation of 2,4-diaminopyrimidine derivatives as novel caspase-1 inhibitors.
Patel S; Modi P; Ranjan V; Chhabria M
Bioorg Chem; 2018 Aug; 78():258-268. PubMed ID: 29614437
[TBL] [Abstract][Full Text] [Related]
3. Broadening the horizon: Integrative pharmacophore-based and cheminformatics screening of novel chemical modulators of mitochondria ATP synthase towards interventive Alzheimer's disease therapy.
Emmanuel IA; Olotu F; Agoni C; Soliman MES
Med Hypotheses; 2019 Sep; 130():109277. PubMed ID: 31383337
[TBL] [Abstract][Full Text] [Related]
4. Rational approach to identify newer caspase-1 inhibitors using pharmacophore based virtual screening, docking and molecular dynamic simulation studies.
Patel S; Modi P; Chhabria M
J Mol Graph Model; 2018 May; 81():106-115. PubMed ID: 29549805
[TBL] [Abstract][Full Text] [Related]
5. Identification of potent caspase-3 inhibitors for treatment of multi- neurodegenerative diseases using pharmacophore modeling and docking approaches.
Ahmad K; Balaramnavar VM; Baig MH; Srivastava AK; Khan S; Kamal MA
CNS Neurol Disord Drug Targets; 2014; 13(8):1346-53. PubMed ID: 25345515
[TBL] [Abstract][Full Text] [Related]
6. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
7. 'Polymorphism-aided' Selective Targeting and Inhibition of Caspase-6 by a Novel Allosteric Inhibitor Towards Efficient Alzheimer's Disease Treatment.
Kumi RO; Agoni C; Issahaku AR; Olotu FA; Soliman MES
Cell Biochem Biophys; 2020 Sep; 78(3):291-299. PubMed ID: 32592127
[TBL] [Abstract][Full Text] [Related]
8. Study of Caspase 8 Inhibition for the Management of Alzheimer's Disease: A Molecular Docking and Dynamics Simulation.
Ahmad SS; Sinha M; Ahmad K; Khalid M; Choi I
Molecules; 2020 Apr; 25(9):. PubMed ID: 32365525
[TBL] [Abstract][Full Text] [Related]
9. Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases.
Kent CR; Bryja M; Gustafson HA; Kawarski MY; Lenti G; Pierce EN; Knopp RC; Ceja V; Pati B; Walters DE; Karver CE
Bioorg Med Chem Lett; 2016 Nov; 26(22):5476-5480. PubMed ID: 27777011
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore-based virtual screening of catechol-o-methyltransferase (COMT) inhibitors to combat Alzheimer's disease.
Patel CN; Georrge JJ; Modi KM; Narechania MB; Patel DP; Gonzalez FJ; Pandya HA
J Biomol Struct Dyn; 2018 Nov; 36(15):3938-3957. PubMed ID: 29281938
[TBL] [Abstract][Full Text] [Related]
11. Pharmacophore modeling and docking studies on some nonpeptide-based caspase-3 inhibitors.
Sharma S; Basu A; Agrawal RK
Biomed Res Int; 2013; 2013():306081. PubMed ID: 24089669
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel class I and class IIb histone deacetylase inhibitor for Alzheimer's disease therapeutics.
Gupta R; Ambasta RK; Kumar P
Life Sci; 2020 Sep; 256():117912. PubMed ID: 32504755
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of Caspase-1 Inhibition by Four Anti-inflammatory Drugs Used in COVID-19 Treatment.
Caruso F; Pedersen JZ; Incerpi S; Kaur S; Belli S; Florea RM; Rossi M
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163769
[TBL] [Abstract][Full Text] [Related]
14. Multi-Pharmacophore Modeling of Caspase-3 Inhibitors using Crystal, Dock and Flexible Conformation Schemes.
Kumar SP; Jha PC
Comb Chem High Throughput Screen; 2018; 21(1):26-40. PubMed ID: 29295689
[TBL] [Abstract][Full Text] [Related]
15. Implication of Caspase-3 as a Common Therapeutic Target for Multineurodegenerative Disorders and Its Inhibition Using Nonpeptidyl Natural Compounds.
Khan S; Ahmad K; Alshammari EM; Adnan M; Baig MH; Lohani M; Somvanshi P; Haque S
Biomed Res Int; 2015; 2015():379817. PubMed ID: 26064904
[TBL] [Abstract][Full Text] [Related]
16. Identification of molecular descriptors for design of novel Isoalloxazine derivatives as potential Acetylcholinesterase inhibitors against Alzheimer's disease.
Gurung AB; Aguan K; Mitra S; Bhattacharjee A
J Biomol Struct Dyn; 2017 Jun; 35(8):1729-1742. PubMed ID: 27410776
[TBL] [Abstract][Full Text] [Related]
17. Hybrid Receptor-Bound/MM-GBSA-Per-residue Energy-Based Pharmacophore Modelling: Enhanced Approach for Identification of Selective LTA4H Inhibitors as Potential Anti-inflammatory Drugs.
Appiah-Kubi P; Soliman M
Cell Biochem Biophys; 2017 Mar; 75(1):35-48. PubMed ID: 27914004
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer's agents.
Ambure P; Kar S; Roy K
Biosystems; 2014 Feb; 116():10-20. PubMed ID: 24325852
[TBL] [Abstract][Full Text] [Related]
19. New Caspase-1 inhibitor by scaffold hopping into bio-inspired 3D-fragment space.
Brethon A; Chantalat L; Christin O; Clary L; Fournier JF; Gastreich M; Harris CS; Isabet T; Pascau J; Thoreau E; Roche D; Rodeschini V
Bioorg Med Chem Lett; 2017 Dec; 27(24):5373-5377. PubMed ID: 29157864
[TBL] [Abstract][Full Text] [Related]
20. In silico design and search for acetylcholinesterase inhibitors in Alzheimer's disease with a suitable pharmacokinetic profile and low toxicity.
da Silva VB; de Andrade P; Kawano DF; Morais PA; de Almeida JR; Carvalho I; Taft CA; da Silva CH
Future Med Chem; 2011 Jun; 3(8):947-60. PubMed ID: 21707398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
